Polaryx Therapeutics (NASDAQ:PLYX) Coverage Initiated at Raymond James Financial

Key Points

• Raymond James initiated coverage of Polaryx Therapeutics with a “strong-buy” rating and a $6.00 price target, implying approximately 169% upside from the reported $2.23 share price.
• Analyst opinions are mixed, but MarketBeat reports a consensus “Moderate Buy” rating and an average price target of $7.67; HC Wainwright also issued a “buy” rating with a $7.00 target.
• Polaryx reported a quarterly loss of $0.03 per share, while analysts expect a full-year loss of $0.22 per share. CEO Alex Keun Mo Yang recently bought 88,453 shares, and insiders collectively own 45.82% of the company.

Equities researchers at Raymond James Financial assumed coverage on shares of Polaryx Therapeutics (NASDAQ:PLYX - Get Free Report) in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage set a "strong-buy" rating and a $6.00 price target on the stock. Raymond James Financial's price target would suggest a potential upside of 169.06% from the company's current price.

A number of other research firms have also weighed in on PLYX. Weiss Ratings upgraded shares of Polaryx Therapeutics from a "sell (e-)" rating to a "sell (e)" rating in a research note on Wednesday, July 1st. Zacks Research raised Polaryx Therapeutics to a "hold" rating in a research report on Friday, July 10th. Wall Street Zen cut Polaryx Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, July 12th. Finally, HC Wainwright initiated coverage on Polaryx Therapeutics in a research report on Thursday, July 9th. They set a "buy" rating and a $7.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.67.

Polaryx Therapeutics Stock Performance

Shares of NASDAQ:PLYX opened at $2.23 on Thursday. Polaryx Therapeutics has a 52-week low of $1.86 and a 52-week high of $48.91. The stock has a market capitalization of $111.16 million and a PE ratio of -44.60. The business has a 50-day moving average price of $2.33.

Polaryx Therapeutics (NASDAQ:PLYX - Get Free Report) last issued its earnings results on Monday, March 23rd. The company reported ($0.03) EPS for the quarter. Research analysts expect that Polaryx Therapeutics will post -0.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Alex Keun Mo Yang acquired 88,453 shares of Polaryx Therapeutics stock in a transaction on Wednesday, May 27th. The stock was bought at an average cost of $4.07 per share, for a total transaction of $360,003.71. Following the completion of the transaction, the chief executive officer owned 24,233,249 shares of the company's stock, valued at approximately $98,629,323.43. The trade was a 0.37% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 45.82% of the company's stock.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source